Immuneering (IMRX) Common Equity (2020 - 2026)

Immuneering's Common Equity history runs 7 years deep, the most recent figure standing at $206.5 million for Q1 2026.

• On a quarterly basis, Common Equity rose 393.56% year-over-year to $206.5 million in Q1 2026; TTM through Mar 2026 was $206.5 million, a 393.56% increase from a year earlier, with the FY2025 full-year figure at $218.5 million, up 427.91% from the prior year.
• Common Equity retreated to $206.5 million in Q1 2026 per IMRX's latest filing, from $218.5 million in the prior quarter.
• Across five years, Common Equity topped out at $228.0 million in Q3 2025 and bottomed at $28.9 million in Q2 2025.
• The 5-year median for Common Equity is $104.0 million (2023), against an average of $110.9 million.
• Across the five-year window, Common Equity surged 604.95% in 2022 and sank 56.36% in 2025, its largest moves.
• Year by year, Common Equity stood at $109.9 million in 2022, then declined by 17.55% to $90.6 million in 2023, then plunged by 54.31% to $41.4 million in 2024, then soared by 427.91% to $218.5 million in 2025, then slipped by 5.48% to $206.5 million in 2026.
• Per Business Quant, the three latest IMRX Common Equity figures stand at $206.5 million (Q1 2026), $218.5 million (Q4 2025), and $228.0 million (Q3 2025).